Benin Management Has Increased Chevron New (CVX) Holding By $452,400; ROCHE HOLDING LTD SPONS (RHHBY) SI Increased By 47.5%

December 10, 2017 - By Ellis Scott

Benin Management Corp increased Chevron Corp New (CVX) stake by 35.2% reported in 2017Q2 SEC filing. Benin Management Corp acquired 4,350 shares as Chevron Corp New (CVX)’s stock declined 3.45%. The Benin Management Corp holds 16,709 shares with $1.74 million value, up from 12,359 last quarter. Chevron Corp New now has $227.77B valuation. The stock increased 0.24% or $0.29 during the last trading session, reaching $119.92. About 4.12 million shares traded. Chevron Corporation (NYSE:CVX) has risen 6.68% since December 10, 2016 and is uptrending. It has underperformed by 10.02% the S&P500.

ROCHE HOLDING LTD SPONS (OTCMKTS:RHHBY) had an increase of 47.5% in short interest. RHHBY’s SI was 2.61 million shares in December as released by FINRA. Its up 47.5% from 1.77M shares previously. With 4.06 million avg volume, 1 days are for ROCHE HOLDING LTD SPONS (OTCMKTS:RHHBY)’s short sellers to cover RHHBY’s short positions. The stock decreased 0.92% or $0.28 during the last trading session, reaching $30.22. About 3.51M shares traded or 102.01% up from the average. Roche Holding AG (OTCMKTS:RHHBY) has 0.00% since December 10, 2016 and is . It has underperformed by 16.70% the S&P500.

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses worldwide. The company has market cap of $211.94 billion. The firm offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. It has a 21.2 P/E ratio. It also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; anti-platelet therapy monitoring; neonatal intensive care; nucleic acid purification; PCR clinical diagnostics and real-time PCR diagnostic systems; pharmacogenomics; physical fitness and platelet function testing; serum work area; urinalysis; and workflow solutions.

Among 5 analysts covering Roche Hldg (OTCMKTS:RHHBY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Roche Hldg had 9 analyst reports since December 2, 2015 according to SRatingsIntel. The stock of Roche Holding AG (OTCMKTS:RHHBY) earned “Overweight” rating by Piper Jaffray on Friday, January 22. Citigroup upgraded the stock to “Buy” rating in Wednesday, December 2 report. The rating was downgraded by Citigroup to “Hold” on Wednesday, October 18. The firm has “Buy” rating by Cowen & Co given on Monday, August 14. As per Monday, September 18, the company rating was maintained by Cowen & Co. The firm has “Hold” rating by Berenberg given on Tuesday, October 24. The company was maintained on Thursday, October 19 by Cowen & Co. The rating was maintained by Cowen & Co with “Buy” on Monday, July 10.

Among 34 analysts covering Chevron Corporation (NYSE:CVX), 23 have Buy rating, 1 Sell and 10 Hold. Therefore 68% are positive. Chevron Corporation had 93 analyst reports since August 4, 2015 according to SRatingsIntel. The company was initiated on Friday, March 18 by Nomura. The stock of Chevron Corporation (NYSE:CVX) has “Buy” rating given on Wednesday, April 12 by Jefferies. Argus Research upgraded it to “Buy” rating and $100 target in Wednesday, December 16 report. The stock has “Outperform” rating by Macquarie Research on Monday, December 21. JP Morgan upgraded the stock to “Overweight” rating in Friday, September 11 report. The firm has “Underperform” rating by BNP Paribas given on Friday, May 26. The rating was maintained by Morgan Stanley on Wednesday, October 18 with “Overweight”. Raymond James downgraded the stock to “Market Perform” rating in Tuesday, March 22 report. The firm has “Hold” rating given on Tuesday, October 3 by Wells Fargo. Evercore upgraded Chevron Corporation (NYSE:CVX) on Tuesday, November 3 to “Buy” rating.